Candel Therapeutics Acquires Bispecific Antibodies and Secures $370 Million in Financing for Autoimmune Drug Development
Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S....
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity